vs
Side-by-side financial comparison of Kimco Realty (KIM) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $558.0M, roughly 1.3× Kimco Realty). Kimco Realty runs the higher net margin — 29.8% vs 19.1%, a 10.7% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 4.0%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 5.6%).
Kimco Realty Corporation, headquartered in Jericho, New York, is a real estate investment trust that invests in shopping centers.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
KIM vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $558.0M | $708.5M |
| Net Profit | $166.3M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 37.2% | 21.6% |
| Net Margin | 29.8% | 19.1% |
| Revenue YoY | 4.0% | 32.0% |
| Net Profit YoY | 23.7% | 15.5% |
| EPS (diluted) | $0.46 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $558.0M | — | ||
| Q4 25 | $542.5M | $708.5M | ||
| Q3 25 | $535.9M | $659.9M | ||
| Q2 25 | $525.2M | $603.3M | ||
| Q1 25 | $536.6M | $558.6M | ||
| Q4 24 | $525.4M | $536.6M | ||
| Q3 24 | $507.6M | $533.3M | ||
| Q2 24 | $500.2M | $528.1M |
| Q1 26 | $166.3M | — | ||
| Q4 25 | $151.2M | $135.1M | ||
| Q3 25 | $137.8M | $111.1M | ||
| Q2 25 | $163.0M | $90.3M | ||
| Q1 25 | $132.8M | $114.6M | ||
| Q4 24 | $166.0M | $117.0M | ||
| Q3 24 | $136.0M | $96.4M | ||
| Q2 24 | $119.7M | $88.4M |
| Q1 26 | 37.2% | — | ||
| Q4 25 | 36.4% | 21.6% | ||
| Q3 25 | 34.9% | 21.5% | ||
| Q2 25 | 39.2% | 20.9% | ||
| Q1 25 | 33.6% | 20.3% | ||
| Q4 24 | 31.7% | 23.4% | ||
| Q3 24 | 33.7% | 21.1% | ||
| Q2 24 | 32.1% | 19.9% |
| Q1 26 | 29.8% | — | ||
| Q4 25 | 27.9% | 19.1% | ||
| Q3 25 | 25.7% | 16.8% | ||
| Q2 25 | 31.0% | 15.0% | ||
| Q1 25 | 24.8% | 20.5% | ||
| Q4 24 | 31.6% | 21.8% | ||
| Q3 24 | 26.8% | 18.1% | ||
| Q2 24 | 23.9% | 16.7% |
| Q1 26 | $0.46 | — | ||
| Q4 25 | — | $4.65 | ||
| Q3 25 | — | $3.86 | ||
| Q2 25 | — | $3.10 | ||
| Q1 25 | — | $3.67 | ||
| Q4 24 | — | $3.67 | ||
| Q3 24 | — | $3.01 | ||
| Q2 24 | — | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $10.4B | $459.1M |
| Total Assets | $19.6B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $211.6M | $497.0M | ||
| Q3 25 | $159.3M | $285.4M | ||
| Q2 25 | $226.6M | $46.3M | ||
| Q1 25 | $131.3M | $441.4M | ||
| Q4 24 | $688.6M | $669.4M | ||
| Q3 24 | $789.0M | $656.9M | ||
| Q2 24 | $126.4M | $510.9M |
| Q1 26 | — | — | ||
| Q4 25 | $7.7B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.0B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $10.4B | — | ||
| Q4 25 | $10.4B | $459.1M | ||
| Q3 25 | $10.5B | $293.6M | ||
| Q2 25 | $10.5B | $172.4M | ||
| Q1 25 | $10.6B | $593.6M | ||
| Q4 24 | $10.7B | $825.5M | ||
| Q3 24 | $10.5B | $881.4M | ||
| Q2 24 | $10.6B | $763.6M |
| Q1 26 | $19.6B | — | ||
| Q4 25 | $19.7B | $2.0B | ||
| Q3 25 | $19.9B | $1.8B | ||
| Q2 25 | $19.8B | $1.6B | ||
| Q1 25 | $19.7B | $1.9B | ||
| Q4 24 | $20.3B | $2.1B | ||
| Q3 24 | $20.1B | $2.1B | ||
| Q2 24 | $19.5B | $1.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.74× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $258.4M | $192.7M | ||
| Q3 25 | $332.4M | $246.2M | ||
| Q2 25 | $305.4M | $148.5M | ||
| Q1 25 | $223.8M | $125.8M | ||
| Q4 24 | $239.5M | $190.7M | ||
| Q3 24 | $295.9M | $149.1M | ||
| Q2 24 | $294.1M | $116.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $188.1M | ||
| Q3 25 | — | $235.5M | ||
| Q2 25 | — | $142.4M | ||
| Q1 25 | $205.4M | $115.8M | ||
| Q4 24 | — | $183.0M | ||
| Q3 24 | — | $138.5M | ||
| Q2 24 | — | $103.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 35.7% | ||
| Q2 25 | — | 23.6% | ||
| Q1 25 | 38.3% | 20.7% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | — | 26.0% | ||
| Q2 24 | — | 19.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 3.4% | 1.8% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.71× | 1.43× | ||
| Q3 25 | 2.41× | 2.22× | ||
| Q2 25 | 1.87× | 1.65× | ||
| Q1 25 | 1.69× | 1.10× | ||
| Q4 24 | 1.44× | 1.63× | ||
| Q3 24 | 2.18× | 1.55× | ||
| Q2 24 | 2.46× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KIM
| Revenues from rental properties, net | $552.8M | 99% |
| Management and other fee income | $5.2M | 1% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
